{
  "id": "e2f5fe1b53e54ea7",
  "title": "STAT+: As FDA raises bar in rare diseases, pivotal moment nears for RegenxBio",
  "description": "A prominent biotech investor weighs in on the pros and the cons of the FDA's new regime.",
  "content": "A prominent biotech investor weighs in on the pros and the cons of the FDA's new regime.",
  "source": "STAT",
  "source_url": "https://www.statnews.com/2026/01/22/biotech-rare-diseases-regenxbio-cytokinetics/?utm_campaign=rss",
  "published_at": "2026-01-22T11:30:00+00:00",
  "fetched_at": "2026-01-23T00:24:24.269073+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "ai",
    "fda"
  ],
  "location": null,
  "raw_data": {
    "title": "STAT+: As FDA raises bar in rare diseases, pivotal moment nears for RegenxBio",
    "description": "A prominent biotech investor weighs in on the pros and the cons of the FDA's new regime.",
    "url": "https://www.statnews.com/2026/01/22/biotech-rare-diseases-regenxbio-cytokinetics/?utm_campaign=rss",
    "published": "2026-01-22T11:30:00+00:00",
    "source": "STAT"
  }
}